The FDA approved depemokimab, an anti‑inflammatory biologic from GSK, as an add‑on treatment for patients aged 12 and older with certain severe asthma indications. GSK projects peak sales in the region of £3 billion (~$4 billion) and positions depemokimab to compete in the high‑value airway disease market. The approval expands therapeutic options for patients with uncontrolled inflammation and gives GSK a new commercial asset in a market dominated by established biologics. Payers and prescribers will watch label positioning and real‑world uptake as GSK rolls out the drug across markets.